lymphoid cells

[mBio] Researchers explored the roles of hepatocyte-derived exosomal microRNAs and B cell activating factor in the extrahepatic diseases of hepatitis C virus infection.

[Exacis Biotherapeutics, Inc. (PR Newswire, Inc.)] Exacis Biotherapeutics, Inc. announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered natural killer cell products to treat cancer.

[OncoResponse] OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced initiation of a Phase I/II study of OR2805 in patients with advanced cancer.

[Blood] Investigators showed that concurrent ASXL1 and NRAS mutations defined a population of chronic myelomonocytic leukemia patients with shorter leukemia-free survival than those with ASXL1 mutation only.

[Hematological Oncology] Scientists address treatment duration and sequence considerations and discuss current targeted treatment dilemmas of chronic lymphocytic leukemia, where they review B cell lymphoma 2 inhibitors and Bruton’s tyrosine kinase in a fixed duration and continuous treatment manner.

[Cellular & Molecular Immunology] Both transplantation of wild-type bone marrow and adoptive transfer of wild-type Treg cells could prevent liver injury in AMPKα1-KO mice.